Glaukos (GKOS) Expected to Announce Quarterly Earnings on Thursday

Glaukos (NYSE:GKOS) is expected to be announcing its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $100.72 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Glaukos Trading Up 4.6 %

Shares of Glaukos stock opened at $153.06 on Tuesday. The company’s fifty day simple moving average is $151.95 and its 200-day simple moving average is $138.62. The company has a market cap of $8.44 billion, a price-to-earnings ratio of -50.68 and a beta of 1.04. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos has a 1 year low of $83.90 and a 1 year high of $163.71.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GKOS shares. UBS Group started coverage on shares of Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 price target on the stock. Truist Financial lifted their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Monday, December 2nd. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Finally, Stifel Nicolaus lifted their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $151.08.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is currently owned by insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.